MediPharm Labs Corp.

TSX:LABS Stock Report

Market Cap: CA$32.0m

MediPharm Labs Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Greg Hunter

Chief executive officer

CA$524.2k

Total compensation

CEO salary percentage55.62%
CEO tenure5.4yrs
CEO ownership0.7%
Management average tenureno data
Board average tenure7.1yrs

Recent management updates

Recent updates

Analysis Article • Aug 14

MediPharm Labs Corp. (TSE:LABS) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

TSX:LABS 1 Year Share Price vs Fair Value Explore MediPharm Labs's Fair Values from the Community and select yours...
Analysis Article • Mar 26

MediPharm Labs Corp.'s (TSE:LABS) Shares Leap 54% Yet They're Still Not Telling The Full Story

MediPharm Labs Corp. ( TSE:LABS ) shareholders have had their patience rewarded with a 54% share price jump in the last...
Analysis Article • Oct 11

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

There wouldn't be many who think MediPharm Labs Corp.'s ( TSE:LABS ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
Analysis Article • May 29

MediPharm Labs (TSE:LABS) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 23

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Despite an already strong run, MediPharm Labs Corp. ( TSE:LABS ) shares have been powering on, with a gain of 31% in...
Analysis Article • Jan 10

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 06

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Apr 17

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

The MediPharm Labs Corp. ( TSE:LABS ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Aug 20

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

The latest analyst coverage could presage a bad day for MediPharm Labs Corp. ( TSE:LABS ), with the analysts making...
Analysis Article • May 21

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

One thing we could say about the analysts on MediPharm Labs Corp. ( TSE:LABS ) - they aren't optimistic, having just...
Analysis Article • Apr 06

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

The latest analyst coverage could presage a bad day for MediPharm Labs Corp. ( TSE:LABS ), with the analysts making...

CEO Compensation Analysis

How has Greg Hunter's remuneration changed compared to MediPharm Labs's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-CA$9m

Dec 31 2025CA$524kCA$292k

-CA$8m

Sep 30 2025n/an/a

-CA$8m

Jun 30 2025n/an/a

-CA$9m

Mar 31 2025n/an/a

-CA$7m

Dec 31 2024CA$548kCA$285k

-CA$11m

Sep 30 2024n/an/a

-CA$12m

Jun 30 2024n/an/a

-CA$13m

Mar 31 2024n/an/a

-CA$14m

Dec 31 2023CA$972kCA$285k

-CA$13m

Sep 30 2023n/an/a

-CA$16m

Jun 30 2023n/an/a

-CA$20m

Mar 31 2023n/an/a

-CA$26m

Dec 31 2022CA$832kCA$285k

-CA$30m

Sep 30 2022n/an/a

-CA$46m

Jun 30 2022n/an/a

-CA$46m

Mar 31 2022n/an/a

-CA$48m

Dec 31 2021CA$828kCA$247k

-CA$55m

Compensation vs Market: Greg's total compensation ($USD370.33K) is above average for companies of similar size in the Canadian market ($USD153.99K).

Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.

CEO

Greg Hunter

5.4yrs
Tenure
CA$524,213
Compensation

Mr. Greg Hunter serves as Chief Financial Officer at MediPharm Labs Corp since February 08, 2021 and its Interim Chief Executive Officer since January 23, 2026. He brings over years of experience as a busi...

Board Members

NamePositionTenureCompensationOwnership
Keith Strachan
Co-Founder & Chair of the Board1.5yrsCA$20.89k2.34%
CA$ 749.5k
John Medland
Independent Director1.1yrsCA$99.67k0.059%
CA$ 19.0k
Michael Bumby
Independent Directorless than a yearCA$73.30kno data
David Pidduck
Director4.3yrsCA$844.56k5.34%
CA$ 1.7m
Miriam McDonald
Member of the Science Advisory Board7.3yrsCA$32.40kno data
Emily Jameson
Independent Director1.1yrsCA$102.74k0.038%
CA$ 12.3k
Leslie Brown
Member of the Science Advisory Board7.3yrsno datano data
Matt Archibald
Member of the Science Advisory Board7.3yrsno datano data
Markus Roggen
Member of the Science Advisory Board7.3yrsno datano data
Arshad Hack
Member of the Science Advisory Board7.3yrsno datano data
Jerry King
Member of the Science Advisory Board7.3yrsno datano data
Carolina Landolt-Marticorena
Member of the Science Advisory Board6.9yrsno datano data
7.1yrs
Average Tenure

Experienced Board: LABS's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 05:21
End of Day Share Price 2026/07/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MediPharm Labs Corp. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Tamy ChenBMO Capital Markets Equity Research
Kimberly Thompson-HedlinCanaccord Genuity